Compare LPTH & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | ADCT |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.1M | 484.4M |
| IPO Year | 1996 | 2020 |
| Metric | LPTH | ADCT |
|---|---|---|
| Price | $12.48 | $4.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.33 | $7.60 |
| AVG Volume (30 Days) | ★ 3.6M | 648.5K |
| Earning Date | 02-11-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $52,787,353.00 | ★ $75,209,000.00 |
| Revenue This Year | $69.00 | $12.48 |
| Revenue Next Year | $24.62 | $5.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 64.15 | 6.35 |
| 52 Week Low | $1.61 | $1.05 |
| 52 Week High | $15.24 | $4.80 |
| Indicator | LPTH | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 57.30 |
| Support Level | $9.80 | $3.66 |
| Resistance Level | $11.57 | $4.10 |
| Average True Range (ATR) | 1.37 | 0.26 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 93.65 | 79.89 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).